Gedeon Richter Acquires Significant Stake in Granata Bio

Granata Bio Acquires Oviva Therapeutics

April 29, 2025

Biotechnology

Granata Bio has acquired Oviva Therapeutics, a women's health biotech developing OVI-586, a first-in-class therapeutic aimed at extending ovarian function and improving reproductive outcomes. The acquisition expands Granata's fertility and women's health pipeline and will advance OVI-586 toward further development for applications including menopause, contraception, and in vitro fertilization (IVF).

Danaher Corporation Acquires Genedata AG

August 19, 2024

Software

Danaher Corporation has acquired Genedata AG, a Basel-based provider of software solutions for biopharmaceutical R&D, and will integrate the company into its Life Sciences segment. The acquisition expands Danaher’s R&D workflow capabilities by adding Genedata’s data-driven informatics and automation tools to accelerate drug discovery and development.

Pfizer Acquires Biohaven Pharmaceutical Holding Company Ltd.

October 3, 2022

Pharmaceuticals

Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for approximately $11.6 billion (at $148.50 per share), bringing the migraine therapy NURTEC ODT (rimegepant), the zavegepant NDA program, and a CGRP-focused pipeline into Pfizer's Internal Medicine portfolio. Prior to closing, Biohaven spun off its non-CGRP assets into a separate publicly traded company, Biohaven Ltd., which Pfizer received a small pro rata stake in.

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.

Demeetra AgBio Acquires Hera BioLabs

January 29, 2026

Biotechnology

Demeetra AgBio has completed the acquisition and full integration of Hera BioLabs, consolidating commercial rights to the hyperactive Super piggyBac transposase platform under Demeetra. The deal brings Hera’s in vitro services into Demeetra’s R&D, winds down Hera’s in vivo services, and positions Demeetra as the definitive commercial licensor for Super piggyBac across research, development, and biomanufacturing use cases.

BioCryst Pharmaceuticals Acquires Astria Therapeutics

January 26, 2026

Biotechnology

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics for an implied transaction value of approximately $700 million, financed with cash on hand and a ~$396.6 million facility provided by funds managed by Blackstone plus ~37.3 million BioCryst shares issued to Astria equity holders. The deal adds Astria's Phase 3 long-acting plasma kallikrein inhibitor navenibart to BioCryst's hereditary angioedema (HAE) portfolio and provides Astria's early-stage atopic dermatitis program (STAR0310) for which BioCryst will pursue strategic alternatives.